KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBT (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed EBT for 4 consecutive years, with -$211.9 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, EBT fell 12.8% year-over-year to -$211.9 million, compared with a TTM value of -$892.9 million through Dec 2023, up 57.91%, and an annual FY2025 reading of -$313.6 million, up 42.72% over the prior year.
  • EBT was -$211.9 million for Q4 2023 at Ginkgo Bioworks Holdings, up from -$302.9 million in the prior quarter.
  • Across five years, EBT topped out at -$26.7 million in Q3 2021 and bottomed at -$1.7 billion in Q4 2021.
  • Average EBT over 4 years is -$361.1 million, with a median of -$196.4 million recorded in 2022.
  • The sharpest move saw EBT tumbled 2825.32% in 2021, then skyrocketed 89.2% in 2022.
  • Year by year, EBT stood at -$59.5 million in 2020, then crashed by 2825.32% to -$1.7 billion in 2021, then surged by 89.2% to -$187.8 million in 2022, then decreased by 12.8% to -$211.9 million in 2023.
  • Business Quant data shows EBT for DNA at -$211.9 million in Q4 2023, -$302.9 million in Q3 2023, and -$173.2 million in Q2 2023.